DDInter1628 DDInter574
Ruxolitinib, formerly known as INCB018424 or INC424, is an anticancer drug and a Janus kinase (JAK) inhibitor. It is a potent and selective inhibitor of JAK1 and JAK2, which are tyrosine kinases involved in cytokine signalling and hematopoiesis. Myeloproliferative neoplasms, such as myelofibrosis and polycythemia vera, are often characterized by aberrant activation of the JAK-STAT pathway, leading to abnormal blood cell counts and thrombotic complications. By inhibiting JAK1 and JAK2, ruxolitinib works to block the dysregulated cell signalling pathways and prevents abnormal blood cell proliferation. Due to a large number of patients with myeloproliferative neoplasms who have JAK2 mutations, ruxolitinib was the first ATP-competitive inhibitor of JAK1 and JAK2 ever developed. Rux
Multiple Sclerosis (MS) is a chronic, debilitating neurological disease that can lead to profound cognitive and physical symptoms, severely affecting quality of life. It is the main cause of neurological disability not caused by trauma in the young adult population of both North America and Europe. Relapsing-remitting forms of MS lead to neurological symptoms that resolve and recur periodically. More than 80% of patients suffering from this disease have relapsing-remitting MS. Diroximel fumarate is a new drug from the fumarate class formulated to treat various relapsing forms of MS. This drug is bioequivalent to [Dimethyl fumarate][A187544,L9626](initially manufactured in 2013), but is less likely to cause gastrointestinal side effects, owing to its unique chemical structure. Diroximel fumarate was formulated by Alkermes in collaboration with Biogen, and was approved by the FDA in October 2019 and by the EMA in November 2021.
Ruxolitinib {u} (Compound) treats {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is treated by {v} (Compound) Bexarotene
Bexarotene {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Diroximel fumarate
Ruxolitinib {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Bexarotene
Bexarotene {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Diroximel fumarate
Ruxolitinib {u} (Compound) causes {v} (Side Effect) Headache
Headache {u} (Side Effect) is caused by {v} (Compound) Bexarotene
Bexarotene {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Diroximel fumarate
Ruxolitinib {u} (Compound) treats {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is palliated by {v} (Compound) Methylprednisolone
Methylprednisolone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Diroximel fumarate
Ruxolitinib {u} (Compound) causes {v} (Side Effect) Bone pain
Bone pain {u} (Side Effect) is caused by {v} (Compound) Cladribine
Cladribine {u} may lead to a major life threatening interaction when taken with {v} Diroximel fumarate
Ruxolitinib {u} (Compound) downregulates {v} (Gene) DDB2
DDB2 {u} (Gene) is upregulated by {v} (Compound) Trifluridine
Trifluridine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Diroximel fumarate
Ruxolitinib {u} (Compound) upregulates {v} (Gene) UBQLN2
UBQLN2 {u} (Gene) is downregulated by {v} (Compound) Trifluridine
Trifluridine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Diroximel fumarate
Ruxolitinib {u} (Compound) binds {v} (Gene) PLK1
PLK1 {u} (Gene) is downregulated by {v} (Compound) Trifluridine
Trifluridine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Diroximel fumarate
Ruxolitinib {u} (Compound) upregulates {v} (Gene) UBQLN2
UBQLN2 {u} (Gene) is upregulated by {v} (Compound) Ponatinib
Ponatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Diroximel fumarate
Ruxolitinib {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Fingolimod
Fingolimod {u} may lead to a major life threatening interaction when taken with {v} Diroximel fumarate
Ruxolitinib (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Bexarotene (Compound) and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate
Ruxolitinib (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Bexarotene (Compound) and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate
Ruxolitinib (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Bexarotene (Compound) and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate
Ruxolitinib (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is palliated by Methylprednisolone (Compound) and Methylprednisolone may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate
Ruxolitinib (Compound) causes Bone pain (Side Effect) and Bone pain (Side Effect) is caused by Cladribine (Compound) and Cladribine may lead to a major life threatening interaction when taken with Diroximel fumarate
Ruxolitinib (Compound) downregulates DDB2 (Gene) and DDB2 (Gene) is upregulated by Trifluridine (Compound) and Trifluridine may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate
Ruxolitinib (Compound) upregulates UBQLN2 (Gene) and UBQLN2 (Gene) is downregulated by Trifluridine (Compound) and Trifluridine may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate
Ruxolitinib (Compound) binds PLK1 (Gene) and PLK1 (Gene) is downregulated by Trifluridine (Compound) and Trifluridine may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate
Ruxolitinib (Compound) upregulates UBQLN2 (Gene) and UBQLN2 (Gene) is upregulated by Ponatinib (Compound) and Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate
Ruxolitinib (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Fingolimod (Compound) and Fingolimod may lead to a major life threatening interaction when taken with Diroximel fumarate